Definitive Healthcare (NASDAQ:DH) Upgraded by Wall Street Zen to Buy Rating

Key Points

• Wall Street Zen upgraded Definitive Healthcare to “buy” from “hold,” but broader analyst sentiment remains negative, with an average “Reduce” rating and a $1.47 price target.
• DH shares opened at $1.05, with a market capitalization of approximately $112 million, after trading between $0.61 and $4.35 over the past year.
• The company slightly beat quarterly EPS estimates at $0.05 versus $0.04 expected, though revenue of $55.2 million fell just short of forecasts and the firm posted a negative net margin of 72.28%.

Definitive Healthcare (NASDAQ:DH - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Sunday, Wall Street Zen reports.

A number of other equities research analysts have also recently commented on the stock. Weiss Ratings reiterated a "sell (e+)" rating on shares of Definitive Healthcare in a research report on Monday, August 31st. Morgan Stanley lowered their price target on shares of Definitive Healthcare from $2.50 to $1.50 and set an "equal weight" rating on the stock in a research report on Tuesday, August 11th. BTIG Research reaffirmed a "neutral" rating on shares of Definitive Healthcare in a research note on Friday, September 4th. Bank of America reiterated an "underperform" rating and issued a $0.70 price objective on shares of Definitive Healthcare in a report on Monday, June 29th. Finally, Deutsche Bank Aktiengesellschaft reissued a "hold" rating and issued a $1.00 target price on shares of Definitive Healthcare in a research note on Wednesday, August 12th. One analyst has rated the stock with a Strong Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Reduce" and an average price target of $1.47.

Definitive Healthcare Stock Performance

DH stock opened at $1.05 on Friday. The firm has a market cap of $112.09 million, a price-to-earnings ratio of -0.66, a PEG ratio of 12.96 and a beta of 1.40. The business's fifty day simple moving average is $0.79 and its two-hundred day simple moving average is $0.92. Definitive Healthcare has a twelve month low of $0.61 and a twelve month high of $4.35. The company has a quick ratio of 1.86, a current ratio of 1.86 and a debt-to-equity ratio of 0.81.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.04 by $0.01. Definitive Healthcare had a positive return on equity of 3.55% and a negative net margin of 72.28%.The firm had revenue of $55.20 million during the quarter, compared to analysts' expectations of $55.47 million. Definitive Healthcare has set its FY 2026 guidance at 0.180-0.200 EPS and its Q3 2026 guidance at 0.040-0.050 EPS. Analysts predict that Definitive Healthcare will post 0.06 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in DH. Raymond James Financial Inc. acquired a new stake in Definitive Healthcare during the second quarter worth $32,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Definitive Healthcare during the 4th quarter worth about $35,000. Bayesian Capital Management LP purchased a new stake in Definitive Healthcare in the 2nd quarter valued at about $55,000. Prelude Capital Management LLC purchased a new stake in Definitive Healthcare in the 3rd quarter valued at about $64,000. Finally, ExodusPoint Capital Management LP acquired a new position in Definitive Healthcare in the fourth quarter valued at about $47,000. 98.67% of the stock is currently owned by institutional investors and hedge funds.

About Definitive Healthcare

Definitive Healthcare NASDAQ: DH is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company's flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.